These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 21595733)

  • 1. Glatiramer acetate treatment directly targets CD11b(+)Ly6G(-) monocytes and enhances the suppression of autoreactive T cells in experimental autoimmune encephalomyelitis.
    Toker A; Slaney CY; Bäckström BT; Harper JL
    Scand J Immunol; 2011 Sep; 74(3):235-243. PubMed ID: 21595733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Do Th2 cells mediate the effects of glatiramer acetate in experimental autoimmune encephalomyelitis?
    Jee Y; Liu R; Bai XF; Campagnolo DI; Shi FD; Vollmer TL
    Int Immunol; 2006 Apr; 18(4):537-44. PubMed ID: 16481342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ.
    Aharoni R; Kayhan B; Eilam R; Sela M; Arnon R
    Proc Natl Acad Sci U S A; 2003 Nov; 100(24):14157-62. PubMed ID: 14614135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A modified superantigen rescues Ly6G- CD11b+ blood monocyte suppressor function and suppresses antigen-specific inflammation in EAE.
    Slaney CY; Toker A; Fraser JD; Harper JL; Bäckström BT
    Autoimmunity; 2013 Jun; 46(4):269-78. PubMed ID: 23374140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glatiramer acetate-specific antibody titres in patients with relapsing / remitting multiple sclerosis and in experimental autoimmune encephalomyelitis.
    Bomprezzi R; Schaefer R; Reese V; Misra A; Vollmer TL; Kala M
    Scand J Immunol; 2011 Sep; 74(3):219-226. PubMed ID: 21615449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glatiramer acetate for the treatment of multiple sclerosis: evidence for a dual anti-inflammatory and neuroprotective role.
    Liblau R
    J Neurol Sci; 2009 Dec; 287 Suppl 1():S17-23. PubMed ID: 20106343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD11b+Ly-6C(hi) suppressive monocytes in experimental autoimmune encephalomyelitis.
    Zhu B; Bando Y; Xiao S; Yang K; Anderson AC; Kuchroo VK; Khoury SJ
    J Immunol; 2007 Oct; 179(8):5228-37. PubMed ID: 17911608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term therapy with glatiramer acetate in multiple sclerosis: effect on T-cells.
    Ragheb S; Abramczyk S; Lisak D; Lisak R
    Mult Scler; 2001 Feb; 7(1):43-7. PubMed ID: 11321193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B cells from glatiramer acetate-treated mice suppress experimental autoimmune encephalomyelitis.
    Kala M; Rhodes SN; Piao WH; Shi FD; Campagnolo DI; Vollmer TL
    Exp Neurol; 2010 Jan; 221(1):136-45. PubMed ID: 19879259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Naïve blood monocytes suppress T-cell function. A possible mechanism for protection from autoimmunity.
    Slaney CY; Toker A; La Flamme A; Bäckström BT; Harper JL
    Immunol Cell Biol; 2011 Jan; 89(1):7-13. PubMed ID: 21060323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacy.
    Teitelbaum D; Brenner T; Abramsky O; Aharoni R; Sela M; Arnon R
    Mult Scler; 2003 Dec; 9(6):592-9. PubMed ID: 14664472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glatiramer acetate-reactive peripheral blood mononuclear cells respond to multiple myelin antigens with a Th2-biased phenotype.
    Dhib-Jalbut S; Chen M; Said A; Zhan M; Johnson KP; Martin R
    J Neuroimmunol; 2003 Jul; 140(1-2):163-71. PubMed ID: 12864985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human and murine CD4 T cell reactivity to a complex antigen: recognition of the synthetic random polypeptide glatiramer acetate.
    Duda PW; Krieger JI; Schmied MC; Balentine C; Hafler DA
    J Immunol; 2000 Dec; 165(12):7300-7. PubMed ID: 11120865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis.
    Duda PW; Schmied MC; Cook SL; Krieger JI; Hafler DA
    J Clin Invest; 2000 Apr; 105(7):967-76. PubMed ID: 10749576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral glatiramer acetate in experimental autoimmune encephalomyelitis: clinical and immunological studies.
    Teitelbaum D; Aharoni R; Klinger E; Kreitman R; Raymond E; Malley A; Shofti R; Sela M; Arnon R
    Ann N Y Acad Sci; 2004 Dec; 1029():239-49. PubMed ID: 15681762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Type II monocytes modulate T cell-mediated central nervous system autoimmune disease.
    Weber MS; Prod'homme T; Youssef S; Dunn SE; Rundle CD; Lee L; Patarroyo JC; Stüve O; Sobel RA; Steinman L; Zamvil SS
    Nat Med; 2007 Aug; 13(8):935-43. PubMed ID: 17676050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoantigen-specific immunosuppression with tolerogenic peripheral blood cells prevents relapses in a mouse model of relapsing-remitting multiple sclerosis.
    Kleist C; Mohr E; Gaikwad S; Dittmar L; Kuerten S; Platten M; Mier W; Schmitt M; Opelz G; Terness P
    J Transl Med; 2016 May; 14(1):99. PubMed ID: 27131971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunomodulation neuroprotection and remyelination - the fundamental therapeutic effects of glatiramer acetate: a critical review.
    Aharoni R
    J Autoimmun; 2014 Nov; 54():81-92. PubMed ID: 24934599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct pathological patterns in relapsing-remitting and chronic models of experimental autoimmune enchephalomyelitis and the neuroprotective effect of glatiramer acetate.
    Aharoni R; Vainshtein A; Stock A; Eilam R; From R; Shinder V; Arnon R
    J Autoimmun; 2011 Nov; 37(3):228-41. PubMed ID: 21752599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic induction of regulatory, cytotoxic CD8+ T cells in multiple sclerosis.
    Tennakoon DK; Mehta RS; Ortega SB; Bhoj V; Racke MK; Karandikar NJ
    J Immunol; 2006 Jun; 176(11):7119-29. PubMed ID: 16709875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.